Integer Holdings Cleared for KKR Acquisition
The company received early regulatory approval for its $5.7 billion merger with private equity firm KKR.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Do you believe the acquisition of medical device companies by large investment firms benefits patients?
Integer Holdings Corporation has received early termination of the Hart-Scott-Rodino waiting period regarding its acquisition by KKR. The transaction, valued at $5.7 billion, remains subject to approval by company stockholders.
Why it matters
This regulatory clearance removes a key hurdle for the proposed merger that would see KKR acquire all outstanding shares of the Plano-based company. The deal represents a significant consolidation in the medical device and components market.
KKR will acquire all outstanding shares of Integer for $127 per share in cash, totaling an enterprise value of $5.7 billion. The deal follows a definitive agreement reached by both firms on August 2, 2026.
The players
Integer Holdings Corporation
Headquartered in Plano, this company is a major developer and manufacturer of high-quality medical technologies and components.
KKR
This global investment firm manages multiple alternative asset classes and is the lead entity in the proposed acquisition of Integer.
The details
Integer filed a definitive proxy statement with the SEC on September 14, 2026, to initiate the formal process for shareholder adoption of the merger agreement. A virtual special meeting is now set for stakeholders to cast their votes on the proposal.
Timeline
August 2, 2026: Integer and KKR entered a definitive merger agreement.
September 8, 2026: The record date for stockholders eligible to vote was set.
September 14, 2026: The company filed its definitive proxy statement with the SEC.
September 30, 2026: Early termination of the HSR waiting period was granted.
October 21, 2026: A virtual special meeting for stockholders will take place.
Market Landscape
The acquisition reflects the ongoing trend of private equity firms targeting specialized medical technology manufacturers to consolidate market share. This transaction mirrors broader industry efforts to scale operations through high-value mergers amid evolving healthcare demand.
The acquisition at $127 per share provides a clear valuation for current stockholders ahead of the upcoming vote. The transition of ownership is expected to be finalized by the end of 2026, potentially altering long-term corporate strategy for the Plano-based firm.
The takeaway
This regulatory milestone brings the $5.7 billion acquisition closer to its projected close by the end of 2026. Shareholders should review the proxy statement filed in September to prepare for the voting process on October 21.
What happens next
Stockholders of record as of September 8, 2026, are scheduled to vote on the merger agreement at a virtual special meeting on October 21, 2026, at 9:00 a.m.
Further reading
For more on the regulatory and business climate in the region, visit the Healthcare section.
More information
View the formal merger documents on the SEC website for company filings.
Live Poll
Do you believe the acquisition of medical device companies by large investment firms benefits patients?
